Mentari Therapeutics (MTRI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.02B. Nama's AI scorecard rates it Hold. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Hold
The sections balance. As of Nov 20, 2026.
Momentum
Lagging · +8.8% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-99.9%
How far the last close sits under the highest price of the past five years.
Market cap
$1.02B
Trailing P/E
—
Price / book
—
Price / sales
—
FCF yield
—
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MTRI earnings
Next report: Feb 10, 2027 (Q4 2026).
MTRI analyst price target
Median target $37.50 from 2 analysts, ranging $33.00 – $42.00.
Nama's AI scorecard currently rates Mentari Therapeutics Hold, a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MTRI report earnings?
Mentari Therapeutics's next scheduled report is on Feb 10, 2027.
What is the MTRI price target?
The median analyst price target from 2 analysts is $37.50, with a range of $33.00 – $42.00.
Is MTRI Shariah compliant?
Nama's AAOIFI-style screen reads Mentari Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.